Cargando…

Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database

It is controversial regarding the treatment allocation for patients with stage I hepatocellular carcinoma (SI-HCC). The aim of the present study was to compare the long-term survival in SI-HCC patients undergoing liver transplantation (LT), liver resection (LR), local tumor destruction (LTD), or non...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhaoping, Chen, Weili, Ouyang, Ting, Liu, Hechun, Cao, Lingling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544265/
https://www.ncbi.nlm.nih.gov/pubmed/33031259
http://dx.doi.org/10.1097/MD.0000000000022118
_version_ 1783591823927672832
author Wu, Zhaoping
Chen, Weili
Ouyang, Ting
Liu, Hechun
Cao, Lingling
author_facet Wu, Zhaoping
Chen, Weili
Ouyang, Ting
Liu, Hechun
Cao, Lingling
author_sort Wu, Zhaoping
collection PubMed
description It is controversial regarding the treatment allocation for patients with stage I hepatocellular carcinoma (SI-HCC). The aim of the present study was to compare the long-term survival in SI-HCC patients undergoing liver transplantation (LT), liver resection (LR), local tumor destruction (LTD), or none. SI-HCC patients diagnosed between 2004 and 2015 were extracted from the SEER 18 registry database. Multivariable Cox models and propensity score matching (PSM) method were used to explore the association between surgical methods and long-term prognosis. A total of 5165 patients with stage I (AJCC, 6th or 7th) HCC were included in the study. Only 36.9% of patients diagnosed with HCC in stage I received surgical therapy. The incidence of LT was decreased over time (P < .001). In the multivariable-adjusted cohort (n = 5165), after adjusting potential confounding factors, a clear prognostic advantage of LT was observed in OS (P < .0001) compared with patients after LR. Patients undergoing LTD had a worse OS in comparison with patients who underwent LR (P < .0001). Patients who received no surgical treatment had the worst OS (P < .0001) among 4 treatment groups. In stratified analyses, the salutary effects of LT vs LR on OS were consistent across all subgroups except for a similar result in the noncirrhotic subgroup (P = .4414). The inferior survival effects of LTD vs LR on OS were consistent across all subgroups, and even in the subgroup with tumor size < 3 cm (P = .0342). In the PSM cohort, patients in LT group showed a better OS (P < .001) than patients in LR group (P < .0001) and patients undergoing LTD had a worse OS compared with patients who underwent LR (P = .00059). In conclusion, LT offered a survival advantage compared with LR among patients with Stage I HCC. LT is the best surgical treatment for stage I HCC in patients with advanced fibrosis, whereas LR provides comparable long-term outcomes to LT in patients without advanced fibrosis and should be considered as the first-line surgical option. LTD can be used as an alternative method when LR and LT are unavailable.
format Online
Article
Text
id pubmed-7544265
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75442652020-10-30 Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database Wu, Zhaoping Chen, Weili Ouyang, Ting Liu, Hechun Cao, Lingling Medicine (Baltimore) 7100 It is controversial regarding the treatment allocation for patients with stage I hepatocellular carcinoma (SI-HCC). The aim of the present study was to compare the long-term survival in SI-HCC patients undergoing liver transplantation (LT), liver resection (LR), local tumor destruction (LTD), or none. SI-HCC patients diagnosed between 2004 and 2015 were extracted from the SEER 18 registry database. Multivariable Cox models and propensity score matching (PSM) method were used to explore the association between surgical methods and long-term prognosis. A total of 5165 patients with stage I (AJCC, 6th or 7th) HCC were included in the study. Only 36.9% of patients diagnosed with HCC in stage I received surgical therapy. The incidence of LT was decreased over time (P < .001). In the multivariable-adjusted cohort (n = 5165), after adjusting potential confounding factors, a clear prognostic advantage of LT was observed in OS (P < .0001) compared with patients after LR. Patients undergoing LTD had a worse OS in comparison with patients who underwent LR (P < .0001). Patients who received no surgical treatment had the worst OS (P < .0001) among 4 treatment groups. In stratified analyses, the salutary effects of LT vs LR on OS were consistent across all subgroups except for a similar result in the noncirrhotic subgroup (P = .4414). The inferior survival effects of LTD vs LR on OS were consistent across all subgroups, and even in the subgroup with tumor size < 3 cm (P = .0342). In the PSM cohort, patients in LT group showed a better OS (P < .001) than patients in LR group (P < .0001) and patients undergoing LTD had a worse OS compared with patients who underwent LR (P = .00059). In conclusion, LT offered a survival advantage compared with LR among patients with Stage I HCC. LT is the best surgical treatment for stage I HCC in patients with advanced fibrosis, whereas LR provides comparable long-term outcomes to LT in patients without advanced fibrosis and should be considered as the first-line surgical option. LTD can be used as an alternative method when LR and LT are unavailable. Lippincott Williams & Wilkins 2020-10-09 /pmc/articles/PMC7544265/ /pubmed/33031259 http://dx.doi.org/10.1097/MD.0000000000022118 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 7100
Wu, Zhaoping
Chen, Weili
Ouyang, Ting
Liu, Hechun
Cao, Lingling
Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database
title Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database
title_full Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database
title_fullStr Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database
title_full_unstemmed Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database
title_short Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database
title_sort management and survival for patients with stage-i hepatocellular carcinoma: an observational study based on seer database
topic 7100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544265/
https://www.ncbi.nlm.nih.gov/pubmed/33031259
http://dx.doi.org/10.1097/MD.0000000000022118
work_keys_str_mv AT wuzhaoping managementandsurvivalforpatientswithstageihepatocellularcarcinomaanobservationalstudybasedonseerdatabase
AT chenweili managementandsurvivalforpatientswithstageihepatocellularcarcinomaanobservationalstudybasedonseerdatabase
AT ouyangting managementandsurvivalforpatientswithstageihepatocellularcarcinomaanobservationalstudybasedonseerdatabase
AT liuhechun managementandsurvivalforpatientswithstageihepatocellularcarcinomaanobservationalstudybasedonseerdatabase
AT caolingling managementandsurvivalforpatientswithstageihepatocellularcarcinomaanobservationalstudybasedonseerdatabase